Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono and BeiGene agree cancer drug research alliance

Merck Serono and BeiGene agree cancer drug research alliance

15th November 2013

Merck Serono has expanded its partnership with the Chinese biotech company BeiGene to include the development of a new cancer therapy.

A global licensing, co-development and commercialisation agreement has been signed for BeiGene-290, a PARP inhibitor therapy that is currently in preclinical development, with clinical trials expected to commence next year.

BeiGene will be responsible for the development of the product in China, while Merck Serono will receive rights to bring the therapy to the rest of the world, in exchange for an upfront fee and milestone-based payments.

This is the second collaboration agreement this year between the two companies, which were recently awarded the 2013 BayHelix-Elsevier Award for alliance of the year.

Dr Susan Jane Herbert, head of global business development and strategy for Merck Serono, said: "Today's announcement highlights our commitment both to establishing strong research and development partnerships in China and also to our partner BeiGene."

This comes after the firm also announced a five-year strategic partnership with Germany's Lead Discovery Centre at the end of last month.ADNFCR-8000103-ID-801661101-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.